Flexion Therapeutics Inc (FLXN) Holdings Boosted by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. raised its position in Flexion Therapeutics Inc (NASDAQ:FLXN) by 6.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 107,550 shares of the specialty pharmaceutical company’s stock after buying an additional 6,336 shares during the period. Schwab Charles Investment Management Inc. owned 0.29% of Flexion Therapeutics worth $2,601,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Capital World Investors boosted its position in Flexion Therapeutics by 2.0% in the second quarter. Capital World Investors now owns 2,538,000 shares of the specialty pharmaceutical company’s stock valued at $51,318,000 after buying an additional 49,000 shares in the last quarter. State Street Corp lifted its position in shares of Flexion Therapeutics by 66.3% during the second quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock worth $27,888,000 after purchasing an additional 549,948 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Flexion Therapeutics by 5.9% during the second quarter. Vanguard Group Inc. now owns 1,054,464 shares of the specialty pharmaceutical company’s stock worth $21,321,000 after purchasing an additional 59,143 shares in the last quarter. Wasatch Advisors Inc. lifted its position in shares of Flexion Therapeutics by 58.7% during the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after purchasing an additional 376,745 shares in the last quarter. Finally, Pictet Asset Management Ltd. lifted its position in shares of Flexion Therapeutics by 27.8% during the third quarter. Pictet Asset Management Ltd. now owns 604,469 shares of the specialty pharmaceutical company’s stock worth $14,616,000 after purchasing an additional 131,673 shares in the last quarter. Hedge funds and other institutional investors own 72.78% of the company’s stock.

Shares of Flexion Therapeutics Inc (NASDAQ FLXN) opened at $23.63 on Thursday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. The firm has a market cap of $939.65, a P/E ratio of -6.73 and a beta of 1.15. Flexion Therapeutics Inc has a 12 month low of $16.51 and a 12 month high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.09). analysts predict that Flexion Therapeutics Inc will post -3.84 EPS for the current year.

A number of brokerages have recently issued reports on FLXN. Royal Bank of Canada set a $44.00 target price on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Sunday, October 29th. BMO Capital Markets reiterated an “outperform” rating and set a $37.00 target price (up from $35.00) on shares of Flexion Therapeutics in a research report on Monday, October 9th. Needham & Company LLC upped their target price on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Northland Securities reiterated a “buy” rating and set a $40.00 target price on shares of Flexion Therapeutics in a research report on Friday, November 10th. Finally, Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $106.25.

In other Flexion Therapeutics news, insider Neil Bodick purchased 2,700 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average cost of $24.49 per share, with a total value of $66,123.00. Following the completion of the purchase, the insider now directly owns 64,605 shares in the company, valued at approximately $1,582,176.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael D. Clayman purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were acquired at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the purchase, the insider now owns 35,395 shares of the company’s stock, valued at $835,322. The disclosure for this purchase can be found here. Insiders own 15.98% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/18/flexion-therapeutics-inc-flxn-holdings-boosted-by-schwab-charles-investment-management-inc.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply